8-K 1 d8k.htm FORM 8-K Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

December 10, 2003

 


 

KOSAN BIOSCIENCES INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware   000-31633   94-3217016

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

3832 Bay Center Place Hayward, Ca   94545
(Address of principal executive offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (510) 732-8400

 



ITEM  5.   OTHER EVENTS

 

On December 10, 2003 Kosan Biosciences Incorporated, or the Company, entered into a Placement Agent Agreement with SG Cowen Securities Corporation, CIBC World Markets Corp. and Adams, Harkness & Hill, Inc., collectively the Placement Agents, relating to the solicitation of offers for the purchase of up to 3,115,000 shares of the Company’s common stock, $0.001 par value, at an offering price to the public of $9.00 per share. The offering of the common stock is registered under the Securities Act of 1933, as amended, on the Company’s Registration Statement on Form S-3 (Registration File No. 333-108909) and will be made by means of a prospectus, consisting of a base prospectus and a prospectus supplement, which will be filed with the Securities and Exchange Commission.

 

The press release issued by the Company dated December 10, 2003, titled “Kosan Biosciences Announces Pricing of Common Stock in Registered Direct Offering” is attached hereto as Exhibit 99.1 and is herein incorporated by reference.

 

Attached as Exhibit 1.1 to this Current Report on Form 8-K is the Placement Agent Agreement by and among the Company and the Placement Agents, dated December 10, 2003. Attached as Exhibit 5.1 to this Current Report on Form 8-K is the opinion of Cooley Godward LLP relating to the validity of the shares to be issued in the offering.

 

ITEM  7.   FINANCIAL STATEMENTS AND EXHIBITS

 

(c) Exhibits

 

Exhibit Number

  

Description


  1.1

   Placement Agent Agreement by and among Kosan Biosciences Incorporated, SG Cowen Securities Corporation, CIBC World Markets Corp. and Adams, Harkness & Hill, Inc., dated December 10, 2003.

  5.1

   Opinion of Cooley Godward LLP.

23.1

   Consent of Cooley Godward LLP (reference is made to Exhibit 5.1).

99.1

   Press Release titled “Kosan Biosciences Announces Pricing of Common Stock in Registered Direct Offering,” dated December 10, 2003


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

KOSAN BIOSCIENCES INCORPORATED

(Registrant)

By:

  /s/    MICHAEL S. OSTRACH        
 
   

Michael S. Ostrach

President and Chief Operating Officer

 

Dated: December 10, 2003


EXHIBIT INDEX

 

Exhibit Number

  

Description


  1.1

   Placement Agent Agreement by and among Kosan Biosciences Incorporated, SG Cowen Securities Corporation, CIBC World Markets Corp. and Adams, Harkness & Hill, Inc., dated December 10, 2003.

  5.1

   Opinion of Cooley Godward LLP.

23.1

   Consent of Cooley Godward LLP (reference is made to Exhibit 5.1).

99.1

   Press Release titled “Kosan Biosciences Announces Pricing of Common Stock in Registered Direct Offering,” dated December 10, 2003